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INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG 
CANCER: ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND 
PROJECT (HCUP) DATA
Patel B1, Kamal KM1, Atreja N2
1Duquesne University, Pittsburgh, PA, USA, 2Duquesne university, pittsburgh, PA, USA
OBJECTIVES: To assess overall inpatient resource utilization; and to identify patient-, 
and hospital-related predictors of inpatient length of stay (LOS), total charges, and 
inpatient mortality in bronchial and lung cancer. METHODS: A retrospective data-
base analysis was conducted using the 2007 Nationwide Inpatient Sample (NIS) 
database of the Health care Cost and Utilization Project (HCUP). Patient- (age, sex, 
payer) and hospital-related (private, teaching, region) characteristics were included in 
the study. Outcome variables were LOS, total charges, and inpatient mortality. 
Descriptive analysis examined the differences in bronchial and lung cancer-related 
outcome variables. Regression analyses were conducted to investigate the predictors 
of LOS, charges, and inpatient mortality in bronchial and lung cancer. All statistical 
analyses were conducted using SPSS 17.0 version. RESULTS: The hospital discharges 
for bronchial and lung cancer in 2007 NIS were 153,017 (52.38% male, 57.59% in 
age group 65–84). Mean LOS was 7.3 ± 0.1 days, mean charges were $45,473 ± 1,079, 
and inpatient mortality was 11.42%. Majority (89.0%) of the hospitalizations were 
located in metropolitan areas. Most hospitalizations (76.45%) were in private, not-
for-proﬁt hospitals. Medicare was the most common payer for the hospitalizations. 
Total charges were highest for hospitalizations identiﬁed in the Western region 
($65,655) and in private, for proﬁt hospitals ($59,233). Inpatient mortality was 
highest among hospitalizations in non-metropolitan areas (16.06%). CONCLU-
SIONS: Bronchial and lung cancer is the second leading cause of death in United States 
and thus, it is important to characterize resource utilization and important predictors 
for the disease. Patient- and hospital-related characteristics identiﬁed from this study 
will be useful in stratifying high-risk individuals and those with high inpatient resource 
utilization. Disease management programs such as smoking cessation programs can 
be implemented in high-risk population which can improve patient well-being, reduce 
hospitalizations, and promote cost savings.
CANCER – Patient-Reported Outcomes Studies
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EFFECTS OF VA ONCWATCH INTERVENTION ON COLORECTAL 
CANCER SCREENING ADHERENCE
Bian J1, Fisher D2, Lipscomb J3, Ribeiro M1, Byrd-Sellers J1
1Atlanta VAMC, Decatur, GA, USA, 2Duke University, Durham, NC, USA, 3Emory 
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OBJECTIVES: In 2008, the Veterans Integrated Service Network (VISN) 7 imple-
mented the colorectal cancer (CRC) Oncology Watch intervention (OncWatch), an IT 
system aimed at improving screening adherence and expanding use of colonoscopy 
for diagnostic and surveillance follow-ups. This study is to evaluate the effects of the 
OncWatch on CRC screening adherence. METHODS: We used 1998–2009 Veterans 
Affairs (VA) administrative data to construct two cohorts of average-risk, age 50–64 
veterans eligible for CRC screening, one for 2007 and the other for 2009. Average-
risk, age 50–64 veterans across the VA in 2007 or 2009 were included in this study. 
Veterans in a cohort for a year were considered adherent if they completed fecal occult 
blood test during that year, ﬂexible sigmoidoscopy or double-contrast barium enema 
during that year or the 4 previous years, or colonoscopy during that year or the 9 
previous years. Using a difference-in-differences approach, we applied multivariable 
linear probability models with hospitals ﬁxed-effects for estimation. RESULTS: The 
proportions of veterans adherent to screening in VISN 7 (including 9 hospitals) were 
31.62% in 2007 and 34.37% in 2009; and the proportions in the control VISNs 
(including 120 hospitals) 30.27% and 32.33%, respectively. Among the screening 
adherent, the proportions adherent to colonoscopy in VISN 7 were 16.44% in 2007 
and 24.40% in 2009; the proportions in the control VISNs 26.16% and 38.59%, 
respectively. The multivariable analyses showed that OncWatch was associated with 
a one-percentage-point increase in the likelihood of adherence among the veterans 
eligible for screening and a 3-percentage-point decrease in the likelihood of screening 
colonoscopy among the adherent (P < 0.001). CONCLUSIONS: This preliminary 
study suggests that OncWatch slightly increased the overall likelihood of screening 
adherence among average-risk, age 50–64 veterans. However, OncWatch may have 
unintentionally reduced use of screening colonoscopy, possibly because limited colo-
noscopy capacity was diverted from screening indications to diagnostic and surveil-
lance indications.
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A REVIEW AND META-ANALYSIS OF COLORECTAL CANCER UTILITIES
Djalalov S1, Hoch J2, Tomlinson G3
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OBJECTIVES: To perform a systematic review of the literature on the utility weights 
for colorectal cancer (CRC) health states; to determine the effects of study character-
istics and role of “time to/from initial care” on utility values. METHODS: In a sys-
tematic review we identiﬁed 26 articles in English, providing 161 unique utilities for 
CRC health states elicited from 3574 respondents. Some utilities were estimated from 
SF-36 scores. Data were analyzed using Ordinary Least Squares and Linear Mixed- 
Effects with CRC cancer type, condition, stage, time to/from initial care, instrument, 
administration and study design as independent variables. RESULTS: In the base 
model, the estimated utility of the reference case (scenario of a CRC patient on stage 
I-III in continues care and more than 1 year post-operation, rated by using EQ5D/
HUI3) was 0.72. Cancer type, condition, stages, time to/from initial care, instruments 
and study design were associated with utility differences of 0.08 to 0.30 (P < 0.05). 
Utilities derived by using EQ5D/HUI3 instrument were 0.09 lower than SG/TTO, 0.08 
lower than EQ5Dvas and 0.09 lower than SF-36 (P < 0.01) in the base model of OLS 
analysis. Those utilities differences were signiﬁcantly larger in the supplemental model. 
Utilities elicited at “post-operation more than 1 year” were 0.15 higher than “preop-
erative”, 0.30 higher than “post-operation 1 year” in supplemental model. CONCLU-
SIONS: The CRC utilities review shows a lack of quality of life (QoL) studies for 
surveillance and terminal care that might cause high level uncertainty in the cost-
effectiveness analysis results. Pre- and post-operative health states and time to/from 
health intervention are important factors that inﬂuence QoL. Utilities appear sensitive 
to factors such as cancer type, time to/from initial care and utility instruments.
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WEIGHTS FOR PNEUMOCCOCAL AND HUMAN PAPILLOMAVIRUS 
DISEASES IN ARGENTINA, CHILE AND THE UNITED KINGDOM
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OBJECTIVES: EQ-5D is a widely used generic health measure. One concern is the 
comparability of EQ5D derived weights of selected health states among different 
countries. Our objective was to estimate and compare EQ-5D health states’ weights 
for pneumoccocal and human papillomavirus (HPV) diseases in three different coun-
tries (Argentina, Chile and United Kingdom (UK). METHODS: Twelve health state 
vignettes (8 pneumococcal, 4 HPV) were designed and administered to a convenience 
sample in order to obtain descriptive data regarding the different disease-related 
EQ-5D health states. Subsequently, country speciﬁc EQ-5D time-trade off-based 
weights were used in order to map descriptive health states into local preference 
weights. Finally, inter-country differences for each condition were compared using 
repeated measures ANOVA. RESULTS: Between July and August 2009, 73 subjects 
(mean age = 31 years, range 22 to 58) successfully responded the questionnaire. Fifty-
three percent of the respondents were female and 96% worked or studied in the health 
sector. For pneumoccocal disease-related health states, utility coefﬁcients’ means 
ranged from −0.331 (sepsis, Chile) to 0.727 (auditive sequelae, Argentina). Regarding 
HPV-related conditions, their mean ranged from 0.152 (cervical cancer, UK) to 0.848 
(CIN1, Argentina). Chile consistently showed the lowest values in pneumococcal states 
and in one HPV state, while those of UK were the lowest in most HPV states. Argen-
tina showed the highest values in both disease groups. Mean differences between 
countries in pneumococcal health states were 0.256 (Argentina-Chile), 0.207(Argen-
tina-UK), and 0.048(Chile-UK); and those for HPV were 0.117 (Argentina-Chile), 
0.133 (Argentina-UK), and 0.017(Chile-UK). Differences in country-speciﬁc values for 
each health state were statistically signiﬁcant (p < 0.001). CONCLUSIONS: Preference 
weights for each condition differed signiﬁcantly between analyzed countries even 
though the same health states´ mix was valued for each. These results stress the 
importance of using local and not international weights in context-speciﬁc decision 
making processes.
PCN105
PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE 
FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) 
IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC 
BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR 
LETROZOLE ALONE
Delea TE1, Sofrygin O1, Amonkar M2
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OBJECTIVES: The EGF30008 trial demonstrated that ﬁrst-line therapy with the 
combination of the anti-HER2 tyrosine kinase inhibitor lapatinib plus the aromatase 
inhibitor letrozole improves progression free survival vs. letrozole plus placebo among 
post-menopausal women with HER2+ and HR+ metastatic breast cancer (MBC). 
Results of analyses of the impact of lapatinib on patient health-related quality of life 
(QoL) based on FACT-B (Breast) questionnaire suggest that QoL was similar across 
treatment groups over 48 weeks. METHODS: This analyses estimated patient utility 
values for the treatment arms of EGF30008 using the FACT-G. Time-trade off (TTO) 
utility values were estimated using responses to 4 items from the FACT-G (Physical 
Well Being [PWB]-lack of energy, PWB-feel sick, Functional Well Being [FWB]-able 
to work, and FWB-able to enjoy life) and a published algorithm derived from 1433 
cancer patients (Dobrez 2007). For each patient in the EGF30008 trial, mean utility 
values were calculated for assessments before vs. on after progression. Pre- and post-
progression utilities were averaged across patients for each treatment group by weight-
ing patient level utilities by the numbers of assessments per patient. RESULTS: Among 
HER2+ patients, mean TTO utility values at baseline were 0.86 (0.10) for letrozole 
and lapatinib (N = 84) and 0.86 (0.09) for letrozole+placebo (N = 73). Mean (SD) 
pre-progression utilities were 0.86 (0.13) for letrozole+lapatinib (N = 102) and 0.88 
(0.13) for letrozole+placebo (N = 87). Utility values post-progression were based 
largely on a single assessment at disease progression for each patient and were 0.82 
(0.12) for letrozole+lapatinib (N = 63) and 0.82 (0.10) for letrozole+placebo (N = 57). 
